Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment

• Published in: Alimentary pharmacology & therapeutics Vol. 48; no. 9; pp. 984 - 992
• Main Authors: Wong, Grace Lai‐Hung, Chan, Henry Lik‐Yuen, Tse, Yee‐Kit, Yip, Terry Cheuk‐Fung, Lam, Kelvin Long‐Yan, Lui, Grace Chung‐Yan, Szeto, Cheuk‐Chun, Wong, Vincent Wai‐Sun
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.11.2018
• Subjects: Clinical trials; Epidermal growth factor receptors; Glomerular filtration rate; Hepatitis; Hepatitis B; Interferon; Kidney diseases; Kidneys; Patients; Renal function; Tenofovir; Territory

Summary Background In clinical trials involving patients with preserved renal function, tenofovir disoproxil fumarate (TDF) use was associated with mild renal impairment in 1% of patients. Aim To compare serial renal function of entecavir (ETV)‐treated, TDF‐treated, and untreated patients with chron...